Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitroMatthias Krusch, Julia Salih, Manuela Schlicke, et al.
Molecular Cancer|March 19, 2013
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoformsKerstin Maria Kampa-Schittenhelm, Michael Charles Heinrich, Figen Akmut, et al.
BMC Cancer|January 18, 2016
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patternsKerstin Maria Kampa-Schittenhelm, Olaf Salitzky, Figen Akmut, et al.
International Journal of Molecular Sciences|April 14, 2026
Transcriptomic Landscape and Regulatory Pathways of Drought Response in Rice (<i>Oryza sativa</i> L.): A Meta-Analysis of Microarray and RNA-Seq DataMaria Kampa, Konstantinos Makropoulos, Aikaterini Goule, et al.
Oncotarget|November 16, 2017
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant <i>KIT</i> D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemiaKerstin Maria Kampa-Schittenhelm, Julia Frey, Lara A Haeusser, et al.
Molecular Cancer|May 28, 2013
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemiaKerstin Maria Kampa-Schittenhelm, Michael Charles Heinrich, Figen Akmut, et al.
Ebiomedicine|April 7, 2019
Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemiaMarcus Matthias Schittenhelm, Bianca Walter, Vasileia Tsintari, et al.
Cell Death & Disease|November 30, 2024
High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)Mihada Bajrami Saipi, Alessia Ruiba, Marcus Matthias Schittenhelm, et al.
Pageof 1